Ubs Group Ag Eq Rx, Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$1.66 - $2.31 $75,538 - $105,116	-45,505 Reduced 13.76%	285,286 $633,000
Q2 2023 Aug 11, 2023	SELL	$1.61 - $1.96 $134,496 - $163,734	-83,538 Reduced 20.16%	330,791 $615,000
Q1 2023 May 12, 2023	SELL	$1.8 - $2.83 $716,252 - $1.13 Million	-397,918 Reduced 48.99%	414,329 $803,000
Q4 2022 Feb 08, 2023	BUY	$2.05 - $5.5 $1.5 Million - $4.02 Million	730,056 Added 888.24%	812,247 $2 Million
Q3 2022 Nov 10, 2022	SELL	$0.94 - $5.99 $31,290 - $199,395	-33,288 Reduced 28.83%	82,191 $407,000
Q2 2022 Aug 10, 2022	BUY	$3.2 - $5.69 $365,686 - $650,236	114,277 Added 9507.24%	115,479 $542,000
Q1 2022 May 16, 2022	SELL	$2.8 - $7.39 $1,817 - $4,796	-649 Reduced 35.06%	1,202 $5,000
Q4 2021 Feb 14, 2022	BUY	$5.92 - $9.98 $10,957 - $18,472	1,851 New	1,851 $13,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.